- Safety and Efficacy of Adjunctive Intra-arterial Tenecteplase
- 2 following Successful Thrombectomy in Patients with Large
- **Vessel Occlusion: A Phase 1/2 Randomized Clinical Trial**
- 5 Xianhua Hou<sup>1\*</sup>, MD, Jiacheng Huang<sup>2,3\*</sup>, MD, Changwei Guo<sup>2\*</sup>, MD Li
- 6 Wang<sup>4\*</sup>, MD, Yuxuan He<sup>1\*</sup>, MD, Lin Chen<sup>1</sup>, MD, Qu Liu<sup>1</sup>, MD, Junhua
- Wu<sup>1</sup>, MD, Min Wu<sup>1</sup>, MD, Thanh N. Nguyen<sup>5</sup>, MD, Raul G. Nogueira<sup>6</sup>,
- 8 MD, Duolao Wang<sup>7</sup>, PhD, Jeffrey L. Saver<sup>8</sup>, MD, Wenjie Zi<sup>2#</sup>, MD,
- 9 Zhenhua Zhou<sup>1#</sup>, MD

### 11 Institutions

4

- 12 1.Department of Neurology, Southwest Hospital, Army Medical
- 13 University, Chongqing, China;
- 2.Department of Neurology, Xinqiao Hospital, Army Medical University,
- 15 Chongqing, China;
- 3.Department of Neurology, The Second Affiliated Hospital of
- 17 Chongqing Medical University, Chongqing, China;
- 4.Department of Neurology, Zigong Third People's Hospital, Zigong,
- 19 Sichuan, China;
- 5. Department of Neurology and Radiology, Boston Medical Center, USA;
- 21 6.UPMC Stroke Institute, Departments of Neurology and Neurosurgery,
- 22 University of Pittsburgh School of Medicine, PA, USA;

- 23 7.Global Health Trials Unit, Liverpool School of Tropical Medicine,
- 24 Liverpool, UK;
- 8.Department of Neurology and Comprehensive Stroke Center, David
- Geffen School of Medicine, University of California, Los Angeles, CA,
- 27 USA.

33

- \* First co-authors.
- # Co-corresponding authors.
- Total words: 2282
- Number of figures: 1
- 34 Corresponding authors:
- 35 Zhenhua Zhou, MD
- Department of Neurology, Southwest Hospital, Army Medical University,
- 30 Gaotanyan Main St., Shapingba District, Chongqing 400038, China.
- E-mail: exploiter001@126.com.
- 40 Wenjie Zi, MD
- Department of Neurology, Xinqiao Hospital, Army Medical University,
- No. 183 Xinqiao Main Street, Shapingba District, Chongqing 400038,
- 43 China
- Email: ziwenjie1981@163.com

Abstract

46

**Background:** Adjunct intra-arterial thrombolysis has been shown to 47 48 potentially improve clinical outcomes in patients with large vessel occlusion (LVO) stroke who have undergone successful endovascular 49 thrombectomy (EVT). Tenecteplase, known for its enhanced fibrin 50 51 specificity and extended activity duration, may be a better choice than alteplase for intra-arterial thrombolysis. However, the optimal dose, 52 53 safety and efficacy of intra-arterial tenecteplase remain unclear. 54 **Objective:** To evaluate the optimal dose, safety and efficacy of adjunctive intra-arterial tenecteplase following successful EVT in LVO 55 patients. 56 **Methods and design:** This study is a two-part, phase Ib/IIa, multicenter, 57 open-label, 14+8 dose-escalation (Part I) and dose-expansion (Part II) 58 59 trial conducted in China involving patients LVO patients who achieved successful EVT (defined as the expanded Thrombolysis in Cerebral 60 Infarction [eTICI] grade of 2b50 or higher) within 24 hours of last known 61 well. In Part Ib, the dose escalation will be conducted in up to four tiers 62 of 14+8 patients, starting at 0.03125 mg/kg, to a planned maximum of 63 0.1875mg/kg, and the primary outcome is symptomatic intracranial 64 65 hemorrhage within 24 hours. In Part IIa, 157 patients will be randomized 66 among two selected safe doses and a placebo, and the primary outcome

will be the proportion of patients with nondisabled outcome (modified 67 Rankin Scale score of 0 to 1) at 90 days. 68 69 **Discussions:** This pivotal trial will provide important data on adjunctive intra-arterial tenecteplase following successful EVT in patients with acute 70 ischemic stroke due to LVO and may support advance of treatment 71 standards. 72 Trial registry number: ChiCTR2300073787 and ChiCTR2400080624 73 74 (www.chictr.org.cn). **Keywords:** Clinical trial, Tenecteplase, Mechanical thrombectomy, 75 Acute ischemic stroke, Large vessel occlusion 76 77 78 79 80 81 82 83

#### Introduction

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

Stroke is one of the leading causes of morbidity and mortality Endovascular worldwide.1 thrombectomy (EVT) currently recommended as the gold standard treatment for acute ischemic stroke caused by large vessel occlusion (LVO).<sup>2</sup> However, a meta-analysis study consisted of five randomized clinical trials indicated that two-thirds of patients had disabled (modified Rankin Scale [mRS] 2-6) outcomes after EVT despite successful reperfusion (defined as the extended Thrombolysis In Cerebral Infarction [eTICI] grade of 2b50 or higher.<sup>3,4</sup> Already infarcted tissue present before the procedure, combined with into lacking sufficient infarct expansion areas macromicrocirculatory reperfusion afterward, may lead to incomplete functional recovery.<sup>5</sup> Previous studies demonstrated that even when successful reperfusion has been achieved after EVT, hypoperfusion is common and this is associated with poor clinical outcomes.<sup>6</sup> Preclinical studies have shown that capillary occlusion, perivascular space obstruction, or distal microembolism from a proximal thrombus may cause incomplete reperfusion of the microcirculation and distal vasculature.<sup>7</sup> Targeting the mirco-thrombi, the Effect of Intra-arterial Alteplase vs Placebo Following Successful Thrombectomy on Functional Outcomes in Patients With Large Vessel Occlusion Acute Ischemic Stroke (CHOICE)

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

study showed that adjuvant intra-arterial thrombolysis after successful reperfusion by EVT could improve excellent functional outcome at 90 days.<sup>8</sup> However, this study was terminated prematurely with a resulting limited sample size. Tenecteplase is a modified form of alteplase, with a longer half-life and greater fibrin specificity.<sup>9,10</sup> After extensive exploration, preliminary research established the optimal dose of intravenous TNK (0.25 mg/kg) for thrombolysis therapy in stroke.<sup>11</sup> In the Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke (EXTEND-IA TNK) study, administering tenecteplase (0.25 mg/kg) prior to thrombectomy resulted in a higher rate of reperfusion and improved functional outcomes compared to alteplase (0.9 mg/kg) in patients with LVO stroke. 10,12 Considering the advantages of tenecteplase, adjuvant intra-arterial administration of tenecteplase may provide greater potential benefits for patients with LVO stroke following successful reperfusion compared with alteplase. However, the optimal dose, efficacy, and safety of intra-arterial tenecteplase following successful reperfusion is unknown. Therefore, we conduct a two-part, phase Ib/IIa, multicenter, open-label, 14+8 dose-escalation (Part 1) and dose-expansion (Part 2) trial to determine the most promising dose to advance to a pivotal trial of intra-arterial tenecteplase following successful thrombectomy in patients with acute ischemic stroke due to LVO within 24h of symptom onset.

### Methods

128

129

135

140

141

142

144

145

146

147

148

Study design

130 The Safety and Efficacy of Adjunctive Intra-arterial Tenecteplase following Successful Thrombectomy in Patients with Large Vessel 131 Occlusion (DATE) is an open-label, randomized, multicenter, Phase Ib/IIa 132 133 clinical trial designed to identify a dose of intra-arterial tenecteplase following successful EVT in patients with acute ischemic stroke due to 134 LVO that shows sufficient evidence of safety and efficacy to advance to a pivotal trial. In designing this protocol, we adhered to the SPIRIT 136 reporting guidelines<sup>13</sup> for clarity and consistency. The DATE trial will be 137 divided into two parts: the first part (Phase Ib) is a pilot dose-escalation 138 safety study, and the second part (Phase IIa) is an exploratory study to 139 assess the safety and potential efficacy of adjunctive intra-arterial tenecteplase after successful EVT in patients with LVO stroke at two different doses. After the completion of Phase Ib, a data safety monitoring board (DSMB) unblinded to study groups will select 2 doses (A or B) to 143 be tested in Phase IIa according to the initial safety results.

## **Dose Escalation (Phase Ib):**

This is a dose escalation trial. During this phase, participants will receive intra-arterial administration of increasing doses of tenecteplase after successful EVT. Patients will be treated with up to 4 escalating dose

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

levels: 0.03125 mg/kg (1/8 i.v dose), 0.0625 mg/kg (1/4 i.v dose), 0.125 mg/kg (1/2 *i.v* dose), and 0.1875 mg/kg (3/4 *i.v* dose). According to the Chinese Acute Anterior Circulatory Ischemic Stroke Endovascular Treatment Registry Study, 13.8% of patients experienced symptomatic intracranial hemorrhage (sICH) within 24 hours of receiving EVT.<sup>14</sup> Using sample sizes typical for dose escalation phase I clinical trials<sup>15,16</sup>, we will use a 14+8 design scheme with sICH occurrence within 24 hours after EVT as the dose-limiting toxicity. At each tier, 14 patients will initially be enrolled. If fewer than 2 of 14 subjects develop sICH, the trial will advance to the next tier. If 2 of the 14 develop sICH, 8 more patients will be enrolled at that dose. If 0-1 of the additional 8 patients develops sICH, the trial will advance to the next tier. If 2 of the additional 8 patients develops sICH or 3 of the first 14 develop sICH, that dose will be deemed not tolerated and the immediately preceding dose will be the estimated maximum tolerated dose. The chart is shown in Figure 1. **Dose Expansion (Phase IIa):** Two doses (A and B) will be chosen by the DSMB and investigators jointly according to the results in Phase Ib. In Phase II, a total of 157 new patients will be enrolled, with 46 patients assigned to the dose A group, 46 patients assigned to the dose B group, and an additional 65 patients allocated to the control group.

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

During this phase, 3 arms will be studied and patients will be randomized with stratification allocation according to two strata: patient age ( $<70 \text{ vs} \ge 70 \text{ years}$ ), and admission NIHSS score ( $<15 \text{ vs} \ge 15$ ), to receive 1 of the 2 selected doses of tenecteplase, or to the control group in a 1:1: $\sqrt{2}$  ratio, which in turn yields probabilities of assignment of 0.293, 0.293, and 0.414, respectively. Patients will be randomly assigned by using a real-time internet-based system. This process is automated which allows for concealment of the sequence of allocation. **Objectives:** The primary objective of this study is to preliminarily assess the safety and efficacy of adjunctive intra-arterial tenecteplase at different doses following successful EVT in patients with acute ischemic stroke due to LVO to determine the promising dose to advance to a pivotal trial. **Outcome:** The study is designed to have two parts with different outcomes. **Dose Escalation (Phase Ib)** • *Primary outcome*: The primary outcome is sICH within 24 hours. • Secondary outcome: 1) 90-day modified mRS score 0-1 (%); 2) Proportion of patients with functional independence (mRS score 0 to 2) at 90 days; 3) Level of disability (ordinal distribution of mRS scores) at 90 days;

4) Favorable shift in reperfusion on the eTICI score after intra-arterial tenecteplase thrombolysis therapy. All post-EVT, pre-IA and final post-IA final, angiograms will be scored at a core lab by central and blinded reviewers using the eTICI and classified as eTICI2b, eTICI2c, and eTICI3. The post treatment angiographies will be scored using the eTICI and classified as "improved", "worsened" or "unchanged" with regard to the pre-IA infusion eTICI score.

- 5) The change from baseline of the NIHSS score to 5–7 days or discharge if earlier;
- 202 6) EQ-5D-3L at 90 days;

7) Mortality within 90 days.

# **Dose Expansion (Phase IIa):**

• *Primary outcome:* The primary outcome will be the proportion of patients with a nondisabled outcome (mRS score of 0 or 1) at 90 ( $\pm$ 14) days. Primary outcome assessments will be performed at 90 ( $\pm$ 14) days by two independent, certified physicians who are blinded to the treatment details. To maintain the reliability, accessibility, and traceability of the mRS score, we will retain a video or audio records of the 90-day follow-up for all patients. If video or audio recordings are unavailable, outcomes will be determined in-person by certified local investigators, who will be also unaware of the treatment assignment.

• Secondary outcomes: 215 1) Proportion of patients with functional independence (mRS score 0 216 217 to 2) at 90 days; 2) Level of disability (ordinal distribution of mRS scores) at 90 days; 218 3) Favorable shift in eTICI score after intra-arterial tenecteplase 219 220 thrombolysis therapy; 4) The change of the NIHSS score from baseline to 5-7 days or 221 discharge; 222 5) EQ-5D-3L at 90 days; 223 224 6) sICH rate within 24 hours; 7) Mortality within 90 days. 225 **Inclusion and exclusion criteria** 226 **Inclusion criteria** 227 228 1) Age  $\geq$ 18 years; 2) Time from last known well within 24 hours; 229 3) Large vessel occlusive stroke in the anterior circulation confirmed 230 by computed tomography angiography/magnetic resonance angiography, 231 including intracranial segment of the internal carotid artery, first or 232 second segment of the middle cerebral artery; 233 4) Alberta Stroke Program Early CT Score (ASPECTS) ≥ 6 based on 234 non-contrast computed tomography; 235 5) National Institutes of Health Stroke Scale (NIHSS) score  $\geq 6$ ; 236

- 6) Successful endovascular thrombectomy (eTICI 2b-3);
- 7) Total pass numbers of thrombectomy procedure  $\leq 3$ ;
- 8) Written informed consent signed by patient or their family
- 240 member.

#### **Exclusion criteria**

- 1) NIHSS score  $\geq 25$ ;
- 2) Intracranial hemorrhage confirmed by computed tomography or
- 244 magnetic resonance imaging;
- 3) Treated by intravenous thrombolysis;
- 246 4) Prestroke mRS score  $\geq 2$ .
- 5) Intraprocedural digital subtraction angiography suggests vessel
- penetration, dissection, or extravasation of contrast medium;
- 6) Pregnant or lactating patients;
- 7) Allergic to contrast agent or Tenecteplase;
- 8) Systolic pressure greater than 185 mmHg or diastolic pressure
- greater than 110 mmHg despite blood pressure lowering treatment;
- 9) Genetic or acquired bleeding disposition with anticoagulation
- factor deficiency or already taking oral anticoagulants within 48 hours
- 255 and INR > 1.7;
- 256 10) Blood glucose < 2.8 mmol/L (50 mg/dl) or > 22.2 mmol/L (400 mg/dl)
- 257 mg/dl), platelets  $< 90*10^9/L$ ;

11) History of bleeding in the last 1 month (gastrointestinal and 258 urinary tract bleeding); 259 260 12) Patients on chronic hemodialysis and severe renal insufficiency (glomerular filtration rate < 30 ml/min or blood creatinine > 220 μmol/L 261 [2.5 mg/dl]);262 13) Any terminal illness with a life expectancy of less than 6 263 months; 264 265 14) Intracranial aneurysm, arteriovenous malformation; 266 15) Brain tumor with occupying mass effect on imaging; 16) Puncture to reperfusion time > 90 min; 267 17) Current participation in another clinical trial; 268 18) Unlikely to be available for 90-day follow-up. 269 Participating center eligibility 270 271 To qualify for participation in this trial, study centers will be mandated to have performed a minimum of 50 endovascular procedures 272 each year. Additionally, all neurointerventionists involved will be 273 required to have over five years of experience in cerebrovascular 274 275 interventions, along with a track record of having performed at least 30 cases of mechanical thrombectomy using stent retriever devices annually. 276 **Enrollment** 277 Before initiating any procedure, participants or their legally 278 authorized representatives will be provided with comprehensive oral and 279

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

written information regarding the study, encompassing its objectives, potential risks, and anticipated benefits. Subsequently, they will be required to give their informed consent. All individuals who fulfill the specified eligibility criteria are eligible for enrollment in the DATE clinical trial. **Study Intervention** Eligible patients assigned to the tenecteplase group will undergo an infusion of intra-arterial tenecteplase with the assigned dose. This infusion will be administered through a distal access catheter or microcatheter positioned proximal to the initially occluded artery. Patients allocated to the control group will terminate the procedure without further intraarterial thrombolysis. All enrolled patients should be monitored in the acute stroke unit and can be admitted to the intensive care unit if necessary. All enrolled patients will undergo standardized medical treatment management and subsequent secondary preventive medication according to the Chinese Guidelines for Endovascular Treatment of Acute ischemic Stroke 2018.<sup>17</sup> Blinding and masking Each participating site will allocate one or more physicians to perform follow-up evaluations at 24-hour intervals, between five to seven days post-treatment, or at the time of discharge if it occurs sooner, along with a 90-day assessment. It is imperative that these physicians are not involved in the subject's initial treatment to ensure their blinding to the treatment assignment.

## Data safety monitoring board

302

303

304

305

306

307

308

309

310

311

312

The independent Data and Safety Monitoring Committee (DSMB) is responsible for reviewing the aggregated data and determining the study safety endpoints. The DSMB regularly reviews the study data added during the trial and advises the sponsor on the continued safety of the subjects and those not yet included in the study. The DSMB advises on the continued effectiveness and scientific value of the study.

## Sample size estimates

### Dose Escalation (Phase Ib):

- The Endovascular Treatment for Acute Anterior Circulation
  Ischemic Stroke registry in China showed that the incidence of sICH
  within 24 hours after EVT was 13.8%. Based on this data, we designed
  a 14+8 enrollment plan as follows:
- 1) 14 subjects will be included in the trial for the first time for each dose;
- 2) If<2 DLT (dose limit toxicity) symptomatic intracranial hemorrhages occur within 24 hours after EVT, the trial advances to the next dose level;
- 3) If 2/14 DLT, then include 8 more people at the same dose;
- 4) If 2/14+0-1/8DLT (13.6%), proceed to the next dose level;

5) If 2/14+2/8 DLT (18.2%) or 3/14 DLT, then this dose is deemed 324 unsafe and the prior lower dose is the MTD. 325 326 Dose Expansion (Phase IIa): In Phase IIa randomization will allocate to randomize 46 subjects each 327 into dose group A and dose group B, and 65 subjects into the control 328 group in a 1:1: $\sqrt{2}$  ratio. This approach is similar to the sample size 329 calculation method used in the APRIL study.<sup>18</sup> 330 331 332 **Statistical analyses** Continuous variables will be summarized with the median, the 333 inter-quartile range, the minimum, and the maximum. Categorical 334 335 variables will be summarized with counts and percentages. Patient compliance with eligibility criteria and treatment administration, major 336 protocol non-compliance, patient withdrawal and the reason for 337 338 withdrawal (e.g., adverse event, protocol non-compliance, lost to follow up, failed to return, consent withdrawal, and other reasons) and 339 assignment to each analysis population will be summarized using 340 341 appropriate statistics by treatment arms. The statistical results of outcome analyses will be provided with 342 point estimates of treatment differences with 95% confidence intervals 343 (CIs). 344

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

The primary outcome in both phase Ib and IIa will be analyzed using generalized linear models from which a risk ratio with its 95% CI will be estimated as a measurement of treatment effect. The secondary outcomes and safety outcomes (binary, continuous and ordinal) will be analyzed using generalized linear models. For non-normal continuous outcome, a win ratio will be estimated as a measurement of treatment effect. A pooled analysis that combines the phase Ib and phase IIa will be performed as supportive analysis. The primary data analyses will adhere to the intention-to-treat principle. Additionally, per-protocol analyses will be conducted as supplementary analyses. All statistical analyses will be described in detail in the statistical analysis plan which will be finalized before the study database lock, and will be performed using SAS version 9.4 (SAS Institute) and R version 4.4.0 or higher (R Foundation for Statistical Computing). The reporting of trial results will conform to the Consolidated Standards of Reporting Trials guidelines for randomized trials. **Ethical considerations** The study adheres to the ethical guidelines outlined in the Declaration of Helsinki. The protocol was approved by the Ethics Committee of the First Affiliated Hospital of the Army Medical University and all participating centers. Any modifications to the trial protocol will only be executed after obtaining further approval from the ethics committee.

#### Discussion

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

Despite advancements in thrombectomy devices and workflow processes, outcomes for patients with LVO remain suboptimal. Adjunctive intra-arterial thrombolysis following successful reperfusion in patients with LVO stroke has the potential to improve functional outcomes, while the optimal dose remains unclear. To our knowledge, the DATE trial is the first to evaluate the safety, efficacy, and dose-response effects of intra-arterial tenecteplase in patients with LVO stroke after successful EVT. The CHOICE study demonstrated the potential benefits of intra-arterial alteplase at a dose equivalent to 1/4 of the standard intravenous thrombolytic dose for patients with acute ischemic stroke due to LVO following successful recanalization. However, it did not conduct a dose escalation exploratory trial, leaving the ideal dose that balances efficacy and safety unknown. Tenecteplase, a third-generation thrombolytic drug, has demonstrated superiority over alteplase in improving excellent functional outcomes and reducing disability at 3 months.<sup>19</sup> There is an important need to determine which dose provides the best balance of efficacy and safety in patients with LVO following successful EVT. Current trials such as POST-TNK<sup>20</sup> and ANGEL-TNK<sup>21</sup> are exploring different doses of intra-arterial tenecteplase in patients with acute ischemic stroke due to

390

393

394

395

396

397

399

401

403

404

405

407

409

410

LVO following successful EVT, using doses of 0.0625 mg/kg, 0.0625 mg/kg, and 0.125 mg/kg, respectively. However, the IA doses in these 391 trials were determined based on a similar fraction of the IV alteplase dose used in CHOICE (one fourth) or were based on trial steering committee 392 recommendation, rather than dose-escalation study. Therefore, this study will provide insight to characterize the optimal dose of adjunctive intra-arterial tenectepalse administration in these patients. The DATE trial enrolled its first patient on July 27, 2023, and as of August 25, 2024 has enrolled 205 subjects. Full study completion (including collection on 3-month outcomes) is expected by November 398 2024. When completed, this trial will provide pivotal data allowing assessment of the optimal dose, safety, and efficacy of intra-arterial 400 tenecteplase in patients with acute ischemic stroke due to LVO following successful EVT. 402 **Funding** The project was supported by the Key Project of Chongqing Science (2023ZDXM025), National Natural Science Foundation of China (No. 82425021), and Health Joint Medical Research Project and the Major 406 Project of Clinical Research Incubation at the First Affiliated Hospital of 408 Army Medical University (2023IITZD01). **Conflicts of interest** 

The author(s) declare the following potential conflicts of interest with

respect to the research, authorship, and/or publication of this article: JLS 411 reports consulting fees for advising on rigorous and safe clinical trial 412 413 design and conduct from Biogen, Boehringer Ingelheim, Genentech, Johnson & Johnson, Phenox, Phillips, Rapid Medical, and Roche. TNN 414 discloses Associate Editor of Stroke, advisory board of Aruna Bio and, 415 416 Brainomix. RGN reports consulting fees for advisory roles with Anaconda, Biogen, Cerenovus, Genentech, Philips, Hybernia, Hyperfine, 417 418 Imperative 419 Care, Medtronic, Phenox, Philips, Prolong Pharmaceuticals, Stryker Neurovascular, Shanghai Wallaby, Synchron, and stock options for 420 advisory roles with Astrocyte, Brainomix, Cerebrotech, Ceretrieve, 421 422 Corindus Vascular Robotics, CrestecBio Inc., Euphrates Vascular, Inc., Vesalio, Viz-AI, RapidPulse and Perfuze. RGN is one of the Principal 423 424 Investigators of ENDOLOW trial. Funding for this project is provided by 425 Cerenovus. RGN is the Principal Investigator of the DUSK trial. Funding 426 for this project is provided by Stryker Neurovascular. RGN is an investor in Viz-AI, Perfuze, Cerebrotech, Reist/Q'Apel Medical, Truvic, Tulavi 427 428 Therapeutics, Vastrax, Piraeus Medical, Brain4Care, Quantanosis AI, and Viseon. T.Nguyen reports Associate Editor of Stroke; advisory board of 429 Brainomix, Aruna Bio; speaker for Genentech and Kaneka. Other 430 431 author(s) declare no potential conflicts of interest with respect to the research, authorship, and/or publication of I article. 432

# **Contributorship:**

- 434 ZZ, WZ, XH, DW, JLS, TNN, and RGN designed and conceptualized the
- study. XH, JH, CG, YH, LW, LC, QL, JW, and MW participated in data
- collection. XH, YH, JH, and CG wrote the manuscript. All authors
- critically revised and approved the manuscript.

# 438 Acknowledgement

439 None.

440

433

# References

- 441 1. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic
- analysis for the Global Burden of Disease Study 2019. *The Lancet Neurology.*
- 443 2021;20(10):795-820.
- 2. Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the Early Management of Patients
- 445 With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management
- 446 of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart
- 447 Association/American Stroke Association. Stroke. 2019;50(12):e344-e418.
- 448 3. Goyal M, Menon B, van Zwam W, et al. Endovascular thrombectomy after large-vessel
- ischaemic stroke: a meta-analysis of individual patient data from five randomised trials.
- 450 Lancet (London, England). 2016;387(10029):1723-1731.
- 451 4. Liebeskind DS, Bracard S, Guillemin F, et al. eTICI reperfusion: defining success in
- 452 endovascular stroke therapy. *J Neurointerv Surg.* 2019;11(5):433-438.
- 453 5. Ng F, Churilov L, Yassi N, et al. Prevalence and Significance of Impaired Microvascular Tissue
- 454 Reperfusion Despite Macrovascular Angiographic Reperfusion (No-Reflow). *Neurology*.
- 455 2022;98(8):e790-e801.
- 456 6. Laredo C, Rodriguez A, Oleaga L, et al. Adjunct Thrombolysis Enhances Brain Reperfusion
- following Successful Thrombectomy. *Ann Neurol.* 2022;92(5):860-870.
- 458 7. Jia M, Jin F, Li S, et al. No-reflow after stroke reperfusion therapy: An emerging phenomenon
- to be explored. CNS neuroscience & therapeutics. 2024;30(2):e14631.
- 460 8. Renú A, Millán M, San Román L, et al. Effect of Intra-arterial Alteplase vs Placebo Following
- 461 Successful Thrombectomy on Functional Outcomes in Patients With Large Vessel Occlusion
- 462 Acute Ischemic Stroke: The CHOICE Randomized Clinical Trial. Jama. 2022;327(9):826-835.
- 463 9. Tsivgoulis G, Katsanos AH, Sandset EC, et al. Thrombolysis for acute ischaemic stroke: current
- status and future perspectives. *The Lancet Neurology*. 2023;22(5):418-429.
- 10. Coutts SB, Berge E, Campbell BC, Muir KW, Parsons MW. Tenecteplase for the treatment of
- acute ischemic stroke: A review of completed and ongoing randomized controlled trials.

467 International journal of stroke: official journal of the International Stroke Society. 468 2018;13(9):885-892. 469 11. Campbell BCV, Mitchell PJ, Churilov L, et al. Effect of Intravenous Tenecteplase Dose on 470 Cerebral Reperfusion Before Thrombectomy in Patients With Large Vessel Occlusion Ischemic 471 Stroke: The EXTEND-IA TNK Part 2 Randomized Clinical Trial. Jama. 2020;323(13):1257-1265. 472 12. Campbell BC, Mitchell PJ, Kleinig TJ, et al. Endovascular therapy for ischemic stroke with 473 perfusion-imaging selection. N Engl J Med. 2015;372(11):1009-1018. 474 13. Chan AW, Tetzlaff JM, Gøtzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance 475 for protocols of clinical trials. BMJ (Clinical research ed). 2013;346:e7586. 476 Zhang X, Xie Y, Wang H, et al. Symptomatic Intracranial Hemorrhage After Mechanical 14. 477 Thrombectomy in Chinese Ischemic Stroke Patients: The ASIAN Score. Stroke. 478 2020;51(9):2690-2696. 479 15. Huang JH, Su QM, Yang J, et al. Sample sizes in dosage investigational clinical trials: a 480 systematic evaluation. Drug design, development and therapy, 2015;9:305-312. 481 16. Yuan Y, Hess KR, Hilsenbeck SG, Gilbert MR. Bayesian Optimal Interval Design: A Simple and 482 Well-Performing Design for Phase | Oncology Trials. Clinical cancer research: an official 483 journal of the American Association for Cancer Research. 2016;22(17):4291-4301. Wang Y, Han S, Qin H, et al. Chinese Stroke Association guidelines for clinical management of 484 17. 485 cerebrovascular disorders: executive summary and 2019 update of the management of 486 high-risk population. Stroke and vascular neurology. 2020;5(3):270-278. 487 18. Hernández-Jiménez M, Abad-Santos F, Cotgreave I, et al. Safety and Efficacy of ApTOLL in 488 Patients With Ischemic Stroke Undergoing Endovascular Treatment: A Phase 1/2 Randomized 489 Clinical Trial. JAMA neurology. 2023;80(8):779-788. 490 19. Palaiodimou L, Katsanos AH, Turc G, et al. Tenecteplase vs Alteplase in Acute Ischemic Stroke 491 Within 4.5 Hours: A Systematic Review and Meta-Analysis of Randomized Trials. Neurology. 492 2024;103(9):e209903. 493 20. Jiacheng Huang CG, Jie Yang, Xiaolei Shi, Chang Liu, Jiaxing Song, Fengli Li, Weilin Kong, Shitao 494 Fan, Zhouzhou Peng, Shihai Yang, Jinfu Ma, Xu Xu, Linyu Li, Zhixi Wang, Nizhen Yu, Wenzhe 495 Sun, Chengsong Yue, Xiang Liu, Dahong Yang, Cheng Huang, Duolao Wang, Raul G. Nogueira, 496 Thanh N. Nguyen, Jeffrey L. Saver, Yangmei Chen, Wenjie Zi. Adjunctive Intra-arterial 497 Tenecteplase after Successful Endovascular Thrombectomy in Patients with Large Vessel 498 Occlusion Stroke (POST-TNK): Study Rationale and Design. European Stroke Journal. 2024. 499 21. Huo X, Luo G, Sun D, et al. Intra-arterial tenecteplase after successful endovascular therapy 500 (ANGEL-TNK): protocol of a multicentre, open-label, blinded end-point, prospective, 501 randomised trial. Stroke and vascular neurology. 2024. 502 503 504

Figure 1. Flow chart for the Phase I of the DATE trial.

